A need for revision of WHO classification of all ductal adenocarcinomas and subtypes of IPMN is suggested, also taking validated and recommended diagnostic use of MUC1 antibody, which recognizes fully glycosylated MUC1, into consideration [125]. The gene discussed is MUC1; the disease is invasive ductal breast carcinoma.